Table 3.
Prevalence of outcomes
| Variable | Patients (n) | Decreased GFRa | Hypomagnesemiaa | Hypophosphatemiaa | Albuminuriaa | Elevated BPa |
|---|---|---|---|---|---|---|
| Therapy subgroup | ||||||
| no nephrotoxic therapy | 546 | 4/524 (0.8) | 3/126 (2.4) | 5/144 (3.5) | 49/477 (10.3) | 96/513 (18.7) |
| ifosfamide | 202 | 29/190 (15.3) | 8/123 (6.5) | 6/139 (4.3) | 48/181 (26.5) | 19/179 (10.6) |
| cisplatin | 112 | 6/108 (5.6) | 17/75 (22.7) | 4/71 (5.6) | 13/94 (13.8) | 15/107 (14.0) |
| carboplatin | 111 | 9/100 (9.0) | 2/50 (4.0) | 2/58 (3.4) | 19/93 (20.4) | 6/92 (6.5) |
| high-dose methotrexate | 368 | 5/349 (1.4) | 7/188 (3.7) | 2/188 (1.1) | 42/331 (12.7) | 25/337 (7.4) |
| high-dose cyclophosphamide | 124 | 9/119 (7.6) | 5/58 (8.6) | 1/64 (1.6) | 13/108 (12.0) | 10/112 (8.9) |
| nephrectomy | 212 | 23/206 (11.2) | 9/44 (20.5) | 1/48 (2.1) | 33/184 (17.9) | 43/198 (21.7) |
| abdominal irradiation | 103 | 14/102 (13.7) | 3/25 (12.0) | 1/32 (3.1) | 18/93 (19.4) | 33/96 (34.4) |
| total-body irradiation | 22 | 1/22 (4.5) | 0/14 (0.0) | 0/14 (0.0) | 5/21 (23.8) | 3/21 (14.3) |
| Therapy combinations | ||||||
| no nephrotoxic therapy | 546 | 4/524 (0.8) | 3/126 (2.4) | 5/144 (3.5) | 49/477 (10.3) | 96/513 (18.7) |
| ifosfamide only | 75 | 11/72 (15.3) | 1/49 (2.0) | 2/58 (3.4) | 21/69 (30.4) | 8/68 (11.8) |
| cisplatin only | 53 | 2/51 (3.9) | 7/31 (22.6) | 2/29 (6.9) | 8/44 (18.2) | 5/49 (10.2) |
| carboplatin only | 23 | 1/21 (4.8) | 0/9 (0.0) | 0/11 (0.0) | 7/20 (35.0) | 1/19 (5.3) |
| platinum agent + ifosfamide | 82 | 9/75 (12.0) | 7/48 (14.6) | 3/53 (5.7) | 12/73 (16.4) | 8/71 (11.3) |
| high-dose methotrexate only | 265 | 2/248 (0.8) | 1/136 (0.7) | 2/130 (1.5) | 31/239 (13.0) | 17/238 (7.1) |
| high-dose cyclophosphamide only | 20 | 0/19 (0.0) | 0/8 (0.0) | 0/9 (0.0) | 1/16 (6.2) | 1/18 (5.6) |
| nephrectomy only | 122 | 8/117 (6.8) | 6/22 (27.3) | 1/23 (4.3) | 13/102 (12.7) | 13/114 (11.4) |
| radiation therapy only | 28 | 1/28 (3.6) | 0/8 (0.0) | 1/10 (10.0) | 5/26 (19.2) | 5/26 (19.2) |
| nephrectomy + NCTx | 13 | 3/13 (23.1) | 0/4 (0.0) | 0/4 (0.0) | 5/13 (38.5) | 2/12 (16.7) |
| nephrectomy + XRT | 65 | 9/65 (13.8) | 3/14 (21.4) | 0/15 (0.0) | 12/60 (20.0) | 27/61 (44.3) |
| nephrectomy + NCTx + XRT | 12 | 3/11 (27.3) | 0/4 (0.0) | 0/6 (0.0) | 3/9 (33.3) | 1/11 (9.1) |
| other NCTx combinations | 118 | 7/114 (6.1) | 8/62 (12.9) | 1/65 (1.5) | 14/102 (13.7) | 9/109 (8.3) |
| radiation therapy + NCTx | 20 | 2/20 (10.0) | 0/13 (0.0) | 0/15 (0.0) | 3/19 (15.8) | 3/19 (15.8) |
| Total | 1442 | 62/1378 (4.5) | 36/534 (6.7) | 17/572 (3.0) | 184/1269 (14.5) | 196/1328 (14.8) |
NCTx, nephrotoxic chemotherapy, defined as high-dose cyclophosphamide, high-dose methotrexate, cisplatin, carboplatin, or ifosfamide; XRT, abdominal radiation therapy and/or total-body irradiation.
a
Values are the number of survivors with a positive test result/total number of survivors tested (percentage). Survivors can belong to more than one therapy subgroup but have received only one therapy combination.